GeoVax Labs, Inc. - Pharmaceuticals & Healthcare

GeoVax Labs, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

GeoVax Labs, Inc. (GeoVax) is a clinical stage biotechnology company focused on research and development activities with a goal to develop, license and commercialize human vaccines for diseases caused by Human Immunodeficiency Virus (HIV) and other infectious agents. The company has exclusively licensed from Emory University certain Acquired Immune Deficiency Syndrome (AIDS) vaccine technology, which was developed in collaboration with the National Institutes of Health and the Centers for Disease Control and Prevention. The company has its operations in Australia, Europe, Japan and North America. The company is headquartered in Atlanta, Georgia in the United States.

Global Market Direct's GeoVax Labs, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.

Scope

• Provides key company information for business intelligence needs
• Gives information on the company's major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
• Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

• A quick ""one-stop-shop"" to understand the company.
• Support sales activities by understanding your customers' businesses.
• Qualify prospective partners and suppliers.
• Understand and respond to your competitors' business structure, strategy and prospects through.
• Understanding the key deals which have shaped the company.

Table Of Contents Table Of Contents 2 List of Tables 3 List of Figures 3 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2004 to YTD 2009 4 GeoVax Labs, Inc., Pharmaceuticals & Healthcare Deals By Type, 2004 to YTD 2009 5 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2004 to YTD 2009 6 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Sector, 2004 to YTD 2009 7 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2004 to YTD 2009 8 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deal Details 9 Acquisition 9 Dauphin Technology Acquires GeoVax 9 Equity Offering 10 GeoVax Labs Completes Private Placement Of $1.37 Million 10 GeoVax Completes Private Placement Of $0.3 Million 11 GeoVax Labs Completes Private Placement Of $2.62 Million 12 GeoVax Labs Completes Private Placement Of $0.25 Million 13 GeoVax Labs Completes Private Placement Of $3 Million 14 Partnerships 15 GeoVax Signs Licensing Agreement With Vivalis 15 GeoVax Extends Its Agreement With Vivalis 16 Key Competitors 17 Key Employees 17 Locations And Subsidiaries 17 Head Office 17 Appendix 18 Methodology 18 About Global Markets Direct 18 Contact Us 18 Disclaimer 18 List of Tables GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2004 to YTD 2009 4 GeoVax Labs, Inc., Pharmaceuticals & Healthcare Deals By Type, 2004 to YTD 2009 5 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2004 to YTD 2009 6 GeoVax Labs, Inc., Deals By Sector, 2004 to YTD 2009 7 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2004 to YTD 2009 8 Dauphin Technology Acquires GeoVax 9 GeoVax Labs Completes Private Placement Of $1.37 Million 10 GeoVax Completes Private Placement Of $0.3 Million 11 GeoVax Labs Completes Private Placement Of $2.62 Million 12 GeoVax Labs Completes Private Placement Of $0.25 Million 13 GeoVax Labs Completes Private Placement Of $3 Million 14 GeoVax Signs Licensing Agreement With Vivalis 15 GeoVax Extends Its Agreement With Vivalis 16 GeoVax Labs, Inc., Key Employees 17 List of Figures GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2004 to YTD 2009 4 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2004 to YTD 2009 5 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2004 to YTD 2009 6 GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals by Sector, 2004 to YTD 2009 7

Healthcare and Pharmaceuticals in Latin America A guide to the markets and regulations Latin America is an extremely promising region for the international pharmaceutical industry, but it is not a straightforward region to operate in and commercial objectives can still be dented by...

India Pharmaceuticals and Healthcare Report Q3 2008 BMI's regional Business Environment Rankings table for Q308 once again finds India in the joint eighth place, alongside Malaysia, both of which are viewed as moderately attractive propositions to multinational...

Argentina Pharmaceuticals and Healthcare Report Q3 2008 BMI has upgraded its 2008 growth forecast for the Argentine pharmaceutical market slightly, with an 8.6% US dollar and 10.0% local currency growth forecast and total market value predicted to...

Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2008 Saudi Arabia accounts for around 65% of pharmaceutical sales in the Gulf Cooperation Council (GCC) region. BMI forecasts that the market should reach US$2.96bn by the end of 2012. The...

Kuwait Pharmaceuticals and Healthcare Report Q3 2009 Kuwait's pharmaceutical market is small in regional terms. Combined sales of over-the-counter (OTC) and prescription drugs reached a total of US$377mn in 2008, and we expect this to reach US$462mn...

View all products in this category